XML 111 R70.htm IDEA: XBRL DOCUMENT v3.20.2

Business Combination (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K)

12 Months Ended

Dec. 31, 2019

Brooklyn Immunotherapeutics, LLC [Member]

Schedule of Purchase Price for Acquisition

The following table details the allocation of the purchase price for the acquisition of BITX:

Cash		$	250,296
Restricted cash			86,000
Prepaid expenses and other current assets			19,998
Security deposits and other assets			379,331
Laboratory equipment			69,597
In process research and development			6,860,000
Accounts payable and accrued expenses			(4,528,969	)
Loans payable			(410,000	)
Loans payable, related parties			(1,500,000	)
Net fair value assigned to assets acquired and liabilities assumed			1,226,253
Goodwill			2,043,747
Total		$	3,270,000

X

- Definition

Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

+ Details

Name:	us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ConsolidatedEntitiesAxis=NTN_BrooklynImmunotherpeuticsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: